Fluid Biopsy Market Size, Share, Trends, Growth Outlook

Fluid Biopsy Market is estimated to increase at a Compounded Annual Growth Rate of 14.5% CAGR over the forecast period from 2024 to 2030

The Fluid Biopsy Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Indication (Lung Cancer, Breast Cancer, Colorectal, Others), By Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA).

An Introduction to Fluid Biopsy Market in 2024

In 2024, the market for fluid biopsy addresses the growing demand for minimally invasive diagnostic tools that enable the detection and characterization of cancer and other diseases through the analysis of bodily fluids such as blood, urine, saliva, cerebrospinal fluid, and pleural effusion. Fluid biopsy, also known as liquid biopsy, offers a non-invasive alternative to traditional tissue biopsies, allowing for the collection and analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles, proteins, and other biomarkers shed by tumors or diseased tissues into the bloodstream or other bodily fluids. Fluid biopsy technologies encompass a variety of methods and platforms, including polymerase chain reaction (PCR), next-generation sequencing (NGS), digital droplet PCR (ddPCR), immunoassays, and microfluidic devices, each offering unique advantages in terms of sensitivity, specificity, and throughput for detecting and quantifying biomarkers of interest. Fluid biopsy has revolutionized cancer diagnostics and personalized medicine by providing real-time insights into tumor heterogeneity, treatment response, minimal residual disease, and the emergence of drug resistance, allowing clinicians to make informed treatment decisions, monitor disease progression, and adjust therapy accordingly. Moreover, fluid biopsy holds promise for the early detection of cancer, screening high-risk populations, and monitoring patients for recurrence following treatment, offering a less invasive and more accessible approach to cancer management. With a focus on precision medicine, diagnostic accuracy, and patient-centered care, fluid biopsy technologies undergo continuous innovation, validation, and clinical validation to demonstrate their clinical utility, reliability, and cost-effectiveness in diverse clinical settings. Furthermore, with advancements in biomarker discovery, microfluidics, artificial intelligence, and data analytics, the fluid biopsy market continues to evolve, offering integrated solutions, multiplexed assays, and point-of-care devices for improving cancer detection, monitoring disease progression, and optimizing patient outcomes across the continuum of cancer care.

Market Trend: Growing Adoption of Liquid Biopsy in Cancer Detection and Monitoring

A prominent trend in the fluid biopsy market is the growing adoption of liquid biopsy techniques for cancer detection and monitoring. Liquid biopsies, which involve analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers in bodily fluids such as blood, urine, and cerebrospinal fluid, offer non-invasive and real-time insights into tumor biology and treatment response. As liquid biopsy technologies continue to evolve and demonstrate clinical utility in various cancer types, they are increasingly being integrated into routine clinical practice for early detection, prognosis assessment, treatment selection, and monitoring of treatment response and disease progression. The trend towards liquid biopsy-based approaches reflects a paradigm shift in cancer diagnostics and personalized medicine, driving market growth in the fluid biopsy segment.

Market Driver: Demand for Minimally Invasive Diagnostic Techniques and Precision Medicine

A key driver for the fluid biopsy market is the demand for minimally invasive diagnostic techniques and precision medicine in oncology. Traditional tissue biopsies, while valuable for diagnosing cancer and guiding treatment decisions, are invasive, associated with procedural risks, and may not always capture tumor heterogeneity or dynamic changes in tumor biology over time. In contrast, liquid biopsies offer a less invasive alternative that enables serial sampling, early detection of treatment resistance, and monitoring of minimal residual disease. The rise of precision medicine approaches, which aim to tailor therapies based on individual patient characteristics and tumor molecular profiles, further drives the demand for liquid biopsy technologies that provide comprehensive molecular insights and guide personalized treatment strategies. The demand for minimally invasive diagnostic techniques and precision oncology solutions fuels market growth and innovation in the fluid biopsy market, driving efforts to improve assay sensitivity, specificity, and clinical utility.

Market Opportunity: Expansion into Early Cancer Detection and Screening Programs

An opportunity for innovation and market expansion in the fluid biopsy market lies in the expansion into early cancer detection and screening programs. While liquid biopsies are primarily used in advanced cancer settings for treatment monitoring and disease surveillance, there is growing interest in leveraging these technologies for population-based screening and early cancer detection initiatives. By detecting tumor-derived biomarkers in asymptomatic individuals at high risk for cancer or as part of routine health screenings, liquid biopsies have the potential to enable earlier diagnosis, improve patient outcomes, and reduce cancer-related morbidity and mortality. Investing in the development of sensitive, cost-effective, and scalable liquid biopsy assays for early cancer detection presents an opportunity for companies to address unmet needs in cancer screening, expand market reach, and contribute to efforts aimed at reducing the global burden of cancer.

Fluid Biopsy Market Share Analysis: Circulating Tumor Cells is the fastest growing segment over the forecast period to 2030

In the Fluid Biopsy Market, the fastest-growing segment is Circulating Tumor Cells (CTCs), primarily driven by its application in various indications such as Lung Cancer, Breast Cancer, Colorectal Cancer, and others. CTCs offer a non-invasive method for detecting and monitoring cancer, providing valuable insights into disease progression, treatment response, and prognosis. The growing emphasis on personalized medicine and early cancer detection has led to increased adoption of CTC-based assays and technologies. As a result, the Circulating Tumor Cells segment is expected to experience substantial growth within the fluid biopsy market, contributing significantly to advancements in cancer diagnostics and treatment monitoring.

Fluid Biopsy Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossBio-Rad Laboratories Inc, Diagnologix LLC, Exosome Sciences Inc, GRAIL Inc, Guardant Health Inc, Horizon Discovery Group plc, Illumina Inc, Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc, Predicine Inc, QIAGEN N.V.

Fluid Biopsy Market Segmentation

By Indication
Lung Cancer
Breast Cancer
Colorectal
Others
By Type
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Fluid Biopsy Market Companies

Bio-Rad Laboratories Inc
Diagnologix LLC
Exosome Sciences Inc
GRAIL Inc
Guardant Health Inc
Horizon Discovery Group plc
Illumina Inc
Inivata Ltd
Lucence Diagnostics Pte Ltd
LungLife AI Inc
Predicine Inc
QIAGEN N.V.

Reasons to Buy the Fluid Biopsy Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Fluid Biopsy Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Fluid Biopsy Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Fluid Biopsy Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Fluid Biopsy Market Size Outlook, $ Million, 2021 to 2030
3.2 Fluid Biopsy Market Outlook by Type, $ Million, 2021 to 2030
3.3 Fluid Biopsy Market Outlook by Product, $ Million, 2021 to 2030
3.4 Fluid Biopsy Market Outlook by Application, $ Million, 2021 to 2030
3.5 Fluid Biopsy Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Fluid Biopsy Industry
4.2 Key Market Trends in Fluid Biopsy Industry
4.3 Potential Opportunities in Fluid Biopsy Industry
4.4 Key Challenges in Fluid Biopsy Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Fluid Biopsy Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Fluid Biopsy Market Outlook by Segments
7.1 Fluid Biopsy Market Outlook by Segments, $ Million, 2021- 2030
By Indication
Lung Cancer
Breast Cancer
Colorectal
Others
By Type
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA

8 North America Fluid Biopsy Market Analysis and Outlook To 2030
8.1 Introduction to North America Fluid Biopsy Markets in 2024
8.2 North America Fluid Biopsy Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Fluid Biopsy Market size Outlook by Segments, 2021-2030
By Indication
Lung Cancer
Breast Cancer
Colorectal
Others
By Type
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA

9 Europe Fluid Biopsy Market Analysis and Outlook To 2030
9.1 Introduction to Europe Fluid Biopsy Markets in 2024
9.2 Europe Fluid Biopsy Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Fluid Biopsy Market Size Outlook by Segments, 2021-2030
By Indication
Lung Cancer
Breast Cancer
Colorectal
Others
By Type
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA

10 Asia Pacific Fluid Biopsy Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Fluid Biopsy Markets in 2024
10.2 Asia Pacific Fluid Biopsy Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Fluid Biopsy Market size Outlook by Segments, 2021-2030
By Indication
Lung Cancer
Breast Cancer
Colorectal
Others
By Type
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA

11 South America Fluid Biopsy Market Analysis and Outlook To 2030
11.1 Introduction to South America Fluid Biopsy Markets in 2024
11.2 South America Fluid Biopsy Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Fluid Biopsy Market size Outlook by Segments, 2021-2030
By Indication
Lung Cancer
Breast Cancer
Colorectal
Others
By Type
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
12 Middle East and Africa Fluid Biopsy Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Fluid Biopsy Markets in 2024
12.2 Middle East and Africa Fluid Biopsy Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Fluid Biopsy Market size Outlook by Segments, 2021-2030
By Indication
Lung Cancer
Breast Cancer
Colorectal
Others
By Type
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Bio-Rad Laboratories Inc
Diagnologix LLC
Exosome Sciences Inc
GRAIL Inc
Guardant Health Inc
Horizon Discovery Group plc
Illumina Inc
Inivata Ltd
Lucence Diagnostics Pte Ltd
LungLife AI Inc
Predicine Inc
QIAGEN N.V.

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Indication
Lung Cancer
Breast Cancer
Colorectal
Others
By Type
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)